Takeda Pharmaceutical Company Limited raised its full-year consolidated earnings forecast for the fiscal year ending March 2027. The expansion in overseas revenue against the backdrop of the weaker yen was cited as a contributing factor.
Takeda Pharmaceutical Company Limited raised its full-year consolidated earnings forecast under International Financial Reporting Standards for the fiscal year ending March 2027. The revisions cover revenue and operating profit, with the company indicating that both are expected to exceed its previous forecasts.
The expansion of overseas revenue due to the weaker yen has been cited as a possible background to the revisions. Although the article does not provide specific amounts or new figures, the contribution of the overseas business is interpreted as a factor behind the improvement in performance.